Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib-Based Primary Treatment for Acute GVHD
NCT06936566Phase 2Recruiting
- Start
- May 2025
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of ruxolitinib in Acute Graft-Versus-Host Disease (aGvHD) (3 arms). Primary endpoint: Day 28 Treatment Response. Started May 2025; status: recruiting.
02
Drugs
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on NCT06936566.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06936566.